Trials / Unknown
UnknownNCT04323579
Validation of Multiparametric Models and Circulating and Imaging Biomarkers to Improve Lung Cancer EARLY Detection.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (estimated)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Accepted
Summary
CLEARLY will focus on validation of a multifactorial "bio-radiomic" protocol for early diagnosis of lung cancer that combines circulating biomarkers and radiomic analysis. It will (a) assess the role of molecular and cellular biomarkers (exosomes, protein signatures, circulating tumor cells - CTCs, microRNA) and radiomic signature, as complementary to assist early detection of lung cancer by low dose computed tomography-LDCT, using bioinformatics techniques; (b) assess the prognostic role of CTCs including the role of cells epithelial mesenchymal transition (EMT) and (c) standardize a method for genomic analysis of CTCs for early detection of treatment resistance.
Conditions
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2021-07-01
- Completion
- 2021-07-01
- First posted
- 2020-03-26
- Last updated
- 2020-03-26
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04323579. Inclusion in this directory is not an endorsement.